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An active pathway for serotonin synthesis by renal proximal tubules.
Serotonin (5HT) has significant effects on renal metabolism and glomer-
ular function and is a potent renal vasoconstrictor. In this study we
describe and localize a highly active biosynthetic pathway for serotonin
in the kidney. Rat kidneys were dissected into cortical and medullary
fractions; in some experiments the cortex was also separated into
subfractions enriched with glomeruli or proximal tubules. Serotonin
and tryptophan hydroxylase (TyOH) were measured by radioenzymatic
techniques.
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Renal denervation did not alter tryptophan hydroxylase activity. In
kidneys from human cadaveric donors, cortical tryptophan hydroxylase
(4.13 0.68 nM/30 min/g) exceeded that in the medulla (1.96 0.86
nM/30 min/g). Aromatic L-amino acid decarboxylase, the remaining
enzyme for serotonin synthesis, is present in both rat renal cortex and
medulla; however, we found 15—fold greater decarboxylase activity in
proximal tubular (2070 nM/30 minlg) as compared to glomerular (131
nM/30 min/g) subfractions. We were able to demonstrate that under
physiological conditions, free urine serotonin reflects actual biosynthe-
sis by the kidney. Thus, although serotonin stores retained by the
kidney appear small and relatively localized to the medulla, the enzy-
matic activity for the synthesis of serotonin in the kidney is comparable
to that in the brain, with the complete pathway localized to renal
cortical proximal tubules. These data suggest that further studies of
renal serotonin metabolism may contribute to our understanding of
renal function in health and disease.
serotonin or its precursors results in a variety of physiologic
effects, and serotonergic receptors which mediate many of
these responses have been identified. In particular, the admin-
istration of serotonin has been shown to have significant effects
on renal metabolism, glomerular function and renal vascular
tone [3, 4]. Furthermore, recently developed serotonin-2 recep-
tor antagonists, such as ketanserin, appear to ameliorate some
forms of hypertension and possibly congestive heart failure [5,
6]. These studies have rekindled an interest in the possible role
of serotonin in the pathophysiology of cardiovascular and renal
disease.
Serotonin is synthesized from its essential amino acid precur-
sor tryptophan. The first step in the conversion is catalyzed by
tryptophan hydroxylase, the rate-limiting enzyme. The result-
ant product, 5-hydroxytryptophan, is subsequently decarboxyl-
ated by aromatic amino acid decarboxylase to serotonin (5-
hydroxytryptamine). Serotonin is degraded primarily by mon-
oamine oxidase and the aldehyde formed is rapidly oxidized to
5-hydroxyindoleacetic acid (5-HIAA).
The kidney, particularly the renal tubular cells of the cortex,
is known to be an extremely rich source of aromatic amino acid
decarboxylase [3, 7, 8, 9]. Substantial monoamine oxidase
activity, also residing almost exclusively in the renal cortex and
in renal tubular cells, has been described as well [3, 10].
However, to our knowledge, no quantitative assessment or
localization of renal tryptophan hydroxylase has been pub-
lished, although its presence in the kidney was qualitatively
identified by Cooper and Melcer [11]. In this study we examine
in more detail the possibility that an active pathway for seroto-
nm biosynthesis exists in the kidney.
Methods
Preparation of tissues
Serotonin is a well established brain neurotransmitter. Rich
stores of serotonin also exist in some tissues outside of the
central nervous system; actual serotonergic nerves have been
identified in the enteric nervous system of mammalian gut [ljj
and in the nodose ganglia [2]. The peripheral administration of
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General. Male Wistar rats, approximately 12 weeks of age,
were used in the experiments characterizing renal serotonin and
its synthesis. A 12 hr light, 12 hr dark cycle was maintained in
the animal housing area. The rats were allowed water, but were
deprived of food for approximately 20 hours prior to the
experiments which were performed from 1000 to 1400 hours.
The rats were anesthetized with pentobarbital (60 mg/kg i.p.)
and heparinized (8,000 U USP/kg). The kidneys were exposed
and flushed free of blood in situ with 10 ml heparinized saline
administered through a hypodermic syringe into a cross
clamped abdominal aorta. The kidneys were removed, cleaned,
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TabLe 1. Serotonin metabolism in the kidney and brainstem of the rat
Proximal
Medulla° Cortexa Glomerulit tubule&' Brainstem5
Serotonin, nglg 21.4 1.5 7.1 0,8* — — 510.7 10.8
Tryptophan Hydroxylase,
nM/30 ininig nd 19.3 0.8* 0.08 0.8 31.3 3.2* 11.9 0.4
Abbreviations: nd, not detectable.
* F < 0.001 proximal tubules vs. glomeruhi or cortex vs. medulla.
a N = 8 for medulla and cortex.
ID N = 6 for nephron fractions and brainstem.
dissected into medulla (including papilla) and cortex on an iced
plate, weighed and then frozen on dry ice. In some experiments
brainstem, consisting of midbrain, pons and medulla, was also
taken for assay. Human kidneys, from cadaveric renal donors
which could not be used for transplant, were also examined.
These kidneys were perfused with blood-free media for approx-
imately 24 hr prior to dissection and assay.
Subfractionation. Proximal tubular fragments were separated
from glomeruli and distal tubular fragments by a modification
[7] of the procedure described by Vinay et al [12]. The method
[7] involves collagenase digestion of kidney cortex slices fol-
lowed by density gradient centrifugation through Percoll. Four
distinct layers were obtained; these were recentrifuged, and the
pellets were allowed to dry for two minutes before weighing to
obtain wet weight. Expressing the results in terms of protein
content had no effect on the value of each fraction relative to
the other. The composition of each fraction was checked by
light microscopy, staining for alkaline phosphatase activity and
gluconeogenic activity. Data for layer one (60 to 80% glomeruli)
and layer four (85 to 95% proximal tubules) are listed in Table
1. Layers two and three which exhibited a mixture of tissue
fractions had intermediate values.
Denervation. Kidneys were surgically denervated by strip-
ping the renal artery and coating it twice for ten minutes each
time with cotton soaked in 10% phenol in alcohol approximately
seven days before assay. Denervation using the neurotoxin
5,7-dihydroxytryptamine, (5,7 dihydroxytryptamine creatinine
sulfate, Regis Chemical Company, Morton Grove, Illinois,
USA) was performed exactly as described by Sole et al [13].
Perfusion. Kidneys from 250 to 350 g male Wistar rats were
prepared for isolated perfusion as previously described [141.
They were perfused with a modified Krebs-Henseleit solution
containing 6.7% dialysed bovine serum albumin (Fraction V,
Miles Laboratory, Toronto, Ontario, Canada), 5 m glucose
and a mixture of 18 amino acids (12.5 mM) containing 0.08 mM
tryptophan. The perfusate was gassed in a water-jacketed film
oxygenator with 95% oxygen/5% carbon dioxide. The perfusion
pH was 7.42 and the temperature was 37.5 to 38°C. Perfusions
were carried out with a renal artery pressure of either 90 mm Hg
or 110 mm Hg. Urine was collected every 10 mm with perfusate
samples taken at the mid point. Tritiated inulin (New England
Nuclear, Boston, Massachusetts, USA) was added to the
perfusate for measurement of inulin clearance. Sodium was
measured by flame photometry and inulin radioactivity was
counted on scintillation counter after adding samples to 11.5 ml
ACS aqueous counting fluid (Amersham Corp., Oakville,
Ontario, Canada) with a total of 1.5 ml water.
Biochemical Assays
Tryptophan hydroxylase. Tryptophan hydroxylase activity
was measured by appropriate modifications to the method of
Waymire et al [15] for tyrosine hydroxylase. In this sensitive
assay, the substrate, carboxyl-labelled tryptophan, is converted
by tryptophan hydroxylase to carboxyl-labelled 5-hydroxytryp-
tophan. The latter amino acid is preferentially decarboxylated
after the addition of an excess amount of aromatic amino acid
decarboxylase, and the radioactive CO2 liberated in the process
is collected and measured. The tissues to be assayed were
harvested as described above; they were then homogenized
with a Polytron homogenizer (Brinkman Industries, Toronto,
Ontario, Canada) in approximately 11 volumes (wt/vol) of ice
cold 0.1 M potassium phosphate buffer, pH 7.4, containing 0.1%
Triton X 100. The homogenates were gently stirred for twenty
minutes at 4°C and then centrifuged for ten minutes at 10,000 g;
the supernatant was taken for assay. The assay medium con-
tained (in a total volume of 320 ,.tl): 220 pi tissue supernatant, 70
tl reaction mixture and 30 jd '4CO2-tryptophan (53.2 mCi/mM).
The reaction mixture was made as follows: 1.275 mg pyridoxal
phosphate and 9.23 mg dl-6-methyl-5, 6, 7, 8-tetrahydropterine
were dissolved in 1.5 ml, 0.01 M sodium phosphate pH 7.0; this
solution was Medium 1. Medium 2 consisted of 1.5 ml, 1 M
potassium phosphate pH 6.2, 40 p1 mercaptoethanol, 0.24 ml
catalase 1:4 with 0.01 M sodium phosphate pH 7, plus water to
a total volume of 5.0 ml. Medium 1(0.75 ml) Medium 2(2.50 ml)
and aromatic amino acid decarboxylase (1.0 ml) were combined
immediately before the assay to constitute the reaction mixture.
Blanks were prepared by boiling the tissue supernatant. The
remainder of the tryptophan hydroxylase procedure (i.e., incu-
bation, termination, collection of '4CO2 and counting) was
exactly as described by Waymire et al [15] for tyrosine hydrox-
ylase. The assay was linear for enzyme content over the 30 mm
incubation. 14C02 collection was complete (100%) two hours
following termination of the reaction by trichloroacetic acid.
Renal cortical specimens gave values which were approxi-
mately 20 times blank.
Aromatic amino acid decarboxylase was prepared from liver
tissue taken from rats pretreated with p-chlorophenylalanine,
100 mg/kg for three successive days, to irreversibly inhibit any
tryptophan hydroxylase activity [16]; the rest of the preparative
procedure was exactly as described by Kizer et al [17]. We were
unable to detect any residual tryptophan hydroxylase activity in
such preparations.
Miscellaneous assays. Serotonin was measured by the radio-
enzymatic method of Hussain and Sole [18]. Tryptophan was
measured by the method of Bloxam and Warren [19]. Blood and
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Table 2. Effect of denervation on rat renal cortical tryptophan
hydroxylase activity (nM/30 min/g)
Study ia Study 2b
Control 20.4 1.6 27.3 0.5
Surgical denervation 21.0 2.1 —
5,7-dihydroxytryptamine — 25.6 2.8
a N = 8.
b N = 3.
platelet poor plasma was prepared and assayed exactly as
described by Hussain and Sole [18]. Catecholamines were
measured by the method of Sole and Hussain [20], modified as
described in Sole et al [21]. Urine cyclic AMP was assayed by
the method of Frandsen and Krishna [22]. Antisera to cyclic
AMP was purchased from Miles-Yeda Ltd. (Elkhart, Indiana,
USA).
Results are expressed as mean SEM. Statistical significance
was calculated using Student's two-tailed t-test (unpaired).
Results
Relatively little serotonin could be found in the kidney;
"stores" in the medulla exceeded those in the cortex approxi-
mately threefold (Table 1). On the other hand, relatively large
levels of tryptophan hydroxylase, the rate-limiting enzyme for
serotonin production, were found. This enzyme was localized
by differential density gradient centrifugation to the proximal
tubular subfraction of the renal cortex where its activity ex-
ceeded that in the brainstem (Table 1). We could not detect
tryptophan hydroxylase activity in heart, aorta, or adrenal
gland, in spite of significant serotonin stores in these organs.
Aromatic amino acid decarboxylase activity was measured and
was also found to be concentrated in the proximal tubular
subfraction (2070 nMI3O minlg proximal tubular vs. 131 nrvx/30
minlg glomerular subfraction).
Renal cortical tryptophan hydroxylase did not appear to be
localized in serotonergic nerve terminals for neither surgical
denervation nor treatment with the neurotoxin 5,7-dihydroxy-
tryptamine had any effect on enzyme levels (Table 2). As
5,7-dihydroxytryptamine is neurotoxic to both noradrenergic
and serotonergic nerve endings, the effectiveness of the admin-
istered regimen was confirmed by a decrease in renal cortical
norepinephrine from 102.3 7.2 nglg to 26.1 5.7 ng/g.
Surgical denervation reduced renal norepinephrine from 109.3
9.7 nglg to 4.85 0.69 nglg,
The ability of the kidney to synthesize serotonin from
tryptophan was confirmed in a series of experiments in the
isolated rat kidney perfused with a solution (free of serotonin
and other amines or 5-hydroxytryptophan) containing 0.08 m
tryptophan, other amino acids and 5 m glucose at 90 mm Hg.
At 35 minutes we found 0.51 .28 ng/ml of serotonin had
accumulated in the recycled perfusate (70 ml). Serotonin pro-
duction in urine collected between 30 and 40 minutes was 0.65
.10 nglminlg. Renal perfusion at 110 mm Hg, although
increasing GFR and sodium excretion, did not affect serotonin
production.
Mammalian urine is known to contain significant quantities of
serotonin. In order to estimate the contribution of renal pro-
Table 3. Effect of inhibition of tryptophan hydroxylase on urine
serotonin (5HT) in rats
Renal cortical
tryptophan
hydroxylase
nM/30 min/g
Urine 5HT
tg/24 hr
Blood SHT
jg/ml
Controla 19.5 2.0 2.13 0.17 2.87 0.62
PCPA 4.4 0.3 0.65 0.09 2.34 0.21
= 8.
bN= 10.
P-chlorophenylalanine (316 mg/kg of the methyl ester ip) was given
to rats between 0900 and 1000 hr. Urine collection began four hr later
and continued for 24 hr at which time blood and kidneys were taken for
analysis.
* P < 0.001, PCPA vs. control.
Table 4. Tryptophan hydroxylase activity (nM/30 min/g) in human
kidney
Patient Medulla Inner cortex Outer cortex Small arteriesa
1 2.52 3.14 4.49 nd
2 0.28 4.15 5.89 nd
3 3.10 4.85 5.40 nd
Abbreviations: nd, not detectable
a hand dissectable, intrarenal arteries (0.5 mm-2.0 mm diameter)
duction, as opposed to that filtered at the glomerulus, we
administered p-chlorophenylalanine (PCPA), a specific inhibi-
tor of tryptophan hydroxylase to rats. PCPA is known to have
no effect on either monoamine oxidase or aromatic amino acid
decarboxylase [16]. Administration of PCPA led to a marked
and proportionate fall in both renal cortical tryptophan hydrox-
ylase activity and urine serotonin excretion. Blood serotonin
exhibited no change (Table 3).
In our next series of experiments we wished to ascertain
whether these results were relevant to man. We obtained three
human kidneys from cadaveric renal donors which ultimately
could not be used for renal transplant. These kidneys were not
affected by disease and had been isolated and perfused for
approximately 24 hr before release for experimentation. Signif-
icant quantities of tryptophan hydroxylase were found in hu-
man kidneys, but the distribution of the enzyme was more
uniformly divided across the kidney than in the rat. Small, but
hand-dissectable intra-renal arteries exhibited no enzyme activ-
ity (Table 4).
We could not administer PCPA to inhibit renal tryptophan
hydroxylase and examine urine serotonin in man. On the other
hand, if renal tryptophan hydroxylase is relatively unsaturated
with its substrate, tryptophan, serotonin synthesis may be
stimulated by the administration of this precursor amino acid
[23]. We provided a dietary supplement of tryptophan to four
normal volunteers. Blood and platelet poor plasma serotonin
did not change after tryptophan administration; however, urine
serotonin reflected plasma tryptophan showing a more than
fivefold increase (Table 5). Urine cyclic AMP remained within
the normal range and did not appear to exhibit a major change
(Table 5).
Discussion
In this study we show that renal tryptophan hydroxylase
activity in the rat is equivalent to, or greater than, that found in
the brain stem. Furthermore, this activity appears localized to
the renal cortex, specifically in a subfraction highly enriched in
proximal tubules. Surgical denervation or the administration of
a serotonergic neurotoxin failed to alter enzymatic activity;
thus, it appeared that renal tryptophan hydroxylase was not
dependent on an extrinsic renal innervation or the presence of
serotonergic nerve terminals.
Although we measured this enzymatic activity in kidney
homogenates, our data appears to meaningfully reflect the
capacity of the whole kidney to synthesize serotonin from its
precursor amino acid tryptophan. We measured the accumula-
tion of significant quantities of serotonin in both the perfusate
and the urine of isolated kidneys perfused by tryptophan-
containing, but an initially 5-hydroxytryptophan and serotonin-
free solution.
Substantive quantities (100 to 500 nglg) of serotonin in the
kidney have been reported by earlier workers. However, these
studies, performed several years ago [24, 25],were incapable of
distinguishing serotonin from related indoles (or many other
interfering substances), and the methods of tissue preparation
suffered from significant contamination by platelets or mast
cells with their accompanying serotonin stores. Using a highly
specific assay for serotonin combined with a careful flushing of
the kidney and stripping of the renal capsule to minimize such
contamination, we found renal serotonin stores to be relatively
small. Whether the threefold increase in medullary, as com-
pared to cortical, serotonin represents an actual heterogeneity
in distribution or a flushing artefact is uncertain.
Serotonin and its major metabolite S-HIAA appear in signif-
icant quantities in mammalian (including human) urine [3, 4, 24,
26]. Sulphate and glucuronide conjugates are also present [3, 4,
26]. The major excretory product is 5-HtAA which is both
filtered at the glomerulus and secreted actively by the renal
tubules [27]. Almost all urinary 5-HIAA is said to come from
the abundant serotonin stores of the gastrointestinal tract [281.
Serotonin presented to the kidney is secreted by the ordinary
organic base transport system [3, 27, 29]. However, systemic
(or parenteral) serotonin administration has virtually no effect
on the levels of free serotonin in the urine, but instead markedly
influences the excretion of 5-HIAA and serotonin conjugates
[30]. Furthermore, in carcinoid syndrome, metabolites of sero-
tonin such as 5-HIAA increase multifold more times in the urine
than does the indolealkylamine itself [26, 31]. These data appear
to reflect the fact that serotonin presented to the bloodstream is
either rapidly sequestered in platelets, or is efficiently metabo-
lized in either the hepatic or pulmonary circulations, leaving
very little available for filtration at the renal glomerulus (this
may not be the case if serotonin metabolism or uptake is
inhibited by drugs or disease). Thus, under physiological con-
ditions at least, it is reasonable to suggest that urine serotonin
may reflect actual biosynthesis by the kidney. Our experiments
support this hypothesis, for we observed a marked decrease in
serotonin excretion in the urine in the absence of a significant
change in blood serotonin levels, following the inhibition of
tryptophan hydroxylase by PCPA (Table 3).
These data also appear to be relevant to man. We found
significant tryptophan hydroxylase activity in the human kid-
ney; there was less cortical but more medullary activity than
that seen in the rat. In order to determine the renal contribution
to serotonin excretion in human urine, we took advantage of the
fact that under most physiological circumstances, tryptophan
hydroxylase is unsaturated relative to its substrate tryptophan,
and thus the availability of this essential amino acid to the
enzyme can be a major determinant of the control of serotonin
synthesis [23]. Tryptophan filtered at the glomerulus appears to
be reabsorbed specifically in the renal proximal tubules [32,
331—the putative major site for renal serotonin synthesis. We,
therefore, administered to human volunteers a dietary supple-
ment of tryptophan which increased plasma tryptophan
severallold; this regimen had no significant effect on blood or
platelet poor plasma serotonin [34, Table 5]. We observed an
approximately fivefold increase in urine serotonin over a period
of six hours following the supplement. Thus, urine serotonin in
man also reflects renal synthesis under physiological condi-
tions. Such a relationship would be expected to facilitate future
studies determining the role of renal serotonin production in
health and disease.
The pathophysiological significance of renal serotonin pro-
duction is speculative. The renal vasoconstrictive effects (par-
ticularly in the renal cortex) of exogenously administered
serotonin are well known [3, 4, 35]. Renal perfusion with
5-hydroxytryptophan (the product of tryptophan hydroxylation
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Volunteer
Table S. Effect
Plasma
of dietary tryptophan supplements on urine serotonin (5HT) and cAMP in normal mana
Urine
tryptophan Blood SilT Urine SilT Urine 5HT x cAMP Urine cAMP x iO
g/ml ng/ml nM/hr 106 creatinine nM/hr creatinine
Control
1 1.98 156 29.2 63.5 66.6 1.47
2 1.01 86 32.0 57.5 — —
3 1,01 153 18.7 38.2 —— —
4 0.96 140 23.9 39.8 70.3 1.17
Tryptophan
7.31 198 190.1 265.7 98.6 1.38
2 3.81 107 147.6 290.1 81.7 1.61
3 8.06 133 145.9 299.1 65.3 1.34
4 6.64 153 99.9 157.6 82.4 1.30
a 1.5 g of L-tryptophan free base (Sigma Chemical Co., St. Louis, MO) was administered in capsule form with breakfast at 0700 and 0800 hour;
[34j. Urine was collected for the next six hours. Blood was taken for analysis at three hours.
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and the immediate precursor of serotonin), has been reported to
increase renal vascular resistance; this response can be blocked
by decarboxylase inhibition or serotonin receptor antagonism
[36].
These data suggest a role for peripheral, perhaps renal,
serotonin as a modulator of renal vascular resistance. We found
no change in serotonin production or excretion, however, in our
isolated perfused kidney experiments when the perfusion pres-
sure was increased from 90 to 110 mmHg. Furthermore, no
measurable tryptophan hydroxylase could be found in the small
intrarenal arteries of human kidney.
Serotonin is a potent stimulator of renal cortical (particularly
glomerular) cyclic AMP [4, 37] and thus renal biosynthesis of
serotonin may be a physiological regulator of glomerular func-
tion, or structure, or play an important role in the pathogenesis
of glomerular disease. Such considerations are particularly
important in light of recent experimental evidence which sug-
gests that manipulation of dietary protein can ameliorate or stop
the progression of chronic renal disease in certain animal
models [38]. We tested these hypotheses only superficially. We
failed to find evidence for tryptophan hydroxylase in the renal
glomerular subfraction. Furthermore, urine cyclic AMP re-
mained within normal limits in spite of a fivefold increase in
urine serotonin excretion after tryptophan feeding (Table 5).
The difficulty in ascribing a biologically significant role for
renal serotonin production exhibits many parallels to similar
problems encountered in studies of renal dopamine. In the
kidney, both compounds have a rapid turnover, low storage and
can be produced outside of monoaminergic nerve terminals
(particularly in the proximal tubules) [14]. Both may influence
presynaptic adrenergic receptors and norepinephnne release
[39, 40, 41]. Also, there is evidence to suggest that both of these
amines have a direct effect on electrolyte transport by tubular
epithelium [3, 42, 43]—but in both cases the evidence is highly
controversial. Both of these amines are also produced by the
carotid body and sensory ganglia, where they may act as
modulators of afferent or reflex nerve traffic [44, 45]. In many
cases these two monoamines appear to have opposing biologi-
cal effects; for example, they have apparently opposite effects
on renal hemodynamics and function [3, 35, 46, 47]. Perhaps
both serotonin and dopamine ultimately function as significant
components of a tubular-glomerular feedback system and a
means of renal auto-regulation.
Finally, one other consideration arises from our studies.
Some assays for tryptophan hydroxylase employ crude prepa-
rations of aromatic amino acid decarboxylase as part of their
methodology [48]. The kidney is a particularly rich and often-
used source of this enzyme. It is evident from the data we have
presented that these semi-purified preparations of kidney
decarboxylase probably contain significant quantities of con-
taminant tryptophan hydroxylase—introducing a potentially
important source of assay artefact. Enzyme derived from
PCPA-treated rat liver as described in this study [17] exhibits no
intrinsic tryptophan hydroxylase activity and thus should be
used in such analyses.
In conclusion, we have shown that the kidney has a consid-
erable extraneural capacity to synthesize serotonin from circu-
lating tryptophan. It appears that the proximal tubules, the site
of tryptophan reabsorption, are most active in this biosynthesis.
Free serotonin in the urine appears to reflect renal production
under physiological conditions. This non-invasive reflection of
synthesis should facilitate future investigations pertaining to the
biological significance of these observations both in animals and
in man.
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